I-Mab to Participate at the Truist Securities BioPharma Symposium
October 28, 2024 | 18:00
I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024 .
Mobile Version